For The Better

While a repeat of 2013 is probably not in the cards, the stock does have risk from the Fed.

The Food and Drug Administration turned down Emergency Use Authorization of lenzilumab in treating hospitalized COVID-19 patients.

A shrinking share count could magnify the software and cloud giant’s impending payout hike.

The notorious meme stock’s quarterly report includes some positives, but the company needs a plan.

Deals with the New York Jets and ROOT SPORTS this week make fuboTV even more appealing.

Mixed results from Apellis Pharmaceuticals are good news for Iveric Bio’s geographic atrophy program.

What goes up must come down.

Put that money to work on investments that pay you back.

The company has a deal to be acquired at a substantial premium.

This fast-growing company increased revenue by over 100% in its most recent quarter.

The latest round of fear, uncertainty, and doubt in the crypto realm is beginning to materialize.

Conflicting clinical trial results for the company’s lead candidate are to blame.

Action camera manufacturer GoPro is staging an impressive comeback. But is it too little, too late?

It is the largest bank in the U.S. and has a high valuation, but there are still lots of areas it can expand in.

Time plus patience, multiplied by sustainable business advantages: the formula for making serious money in the stock market. These three stocks fit the bill.

The brand’s secret sauce for product development continues to deliver impressive growth.

The e-commerce giant is doubling down on its “Just Walk Out” system.

Quarterly results and guidance suggest the company is evolving.

Cybersecurity is a megatrend that has investors very excited. Could cybersecurity awareness training be the next big winner in this space?

Different times of the year can provide fruitful investment opportunities for some stocks. It’s up to you to spot them.